GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News:
“We are pleased to introduce time-lapse as a standard of care and we are confident that the investment in EmbryoScope+ will improve our pregnancy rates and efficiency even further”
Kato Ladies Clinic in Japan, one of the world´s largest IVF clinics, has decided to invest in the newly launched time-lapse system EmbryoScope+. The order comprises eight EmbryoScope+ time-lapse incubators providing the Kato Ladies Clinic with a time-lapse capacity of approximately 6000 treatments per year, making it the largest time-lapse capacity in a single clinic in the world.
The first units will be installed during the fourth quarter 2016 and the remaining units are planned to be installed during the first quarter 2017. Kato Ladies Clinic and Vitrolife have also agreed to perform a joint research project on the application of time-lapse in assisted reproduction, in particular with regards to natural and low stimulation cycles. “We are pleased to introduce time-lapse as a standard of care and we are confident that the investment in EmbryoScope+ will improve our pregnancy rates and efficiency even further”, says Dr Kato, owner of Kato Ladies Clinic.
”It is extremely satisfying that the prestigious Kato Ladies Clinic has decided to invest in EmbryoScope+ and we are delighted to be able to offer the clinic and their customers access to the latest time-lapse technology on the market”, says Marcus Hedenskog, Vitrolife´s regional director in Japan & Pacific.
EmbryoScope+ is a time-lapse system with an integrated incubator. EmbryoScope+ builds on the same foundation as EmbryoScope, the world’s most used time-lapse system for IVF since 2009, but with a larger capacity for 15 patients with up to 16 embryos per patient in a single instrument. EmbryoScope+ has a small footprint, which is an advantage for labs where space is limited and provides an efficient workflow and optimised usage of clinic resources. EmbryoScope+ was presented at the ESHRE conference this summer and was available for purchase from October this year.
Gothenburg, November 18, 2016 VITROLIFE AB (publ) Thomas Axelsson, CEO
Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes.
Vitrolife has approximately 330 employees and the company’s products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, China, Denmark, France, Germany, Hungary, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.
Vitrolife AB (publ)(STO:VITR) , Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/
This information was brought to you by Cision http://news.cision.com
Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14
This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 am CET on November 18, 2016.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
